Lanreotida CAS:108736-35-2

Lanreotida é um análogo sintético da somatostatina, um hormônio inibitório natural que bloqueia a liberação de vários outros hormônios, incluindo hormônio do crescimento, hormônio estimulador da tireoide (TSH), insulina e glucagon.

A lanreotida liga-se aos mesmos receptores que a somatostatina, embora com maior afinidade para receptores periféricos, e tem atividade semelhante. No entanto, enquanto a somatostatina é rapidamente decomposta no corpo (em poucos minutos), lanreotide has a much longer half-life, and produces far more prolonged effects.The efficacy of lanreotide has not been extensively studied, and results differ greatly between trials and formulations.

Lanreotide (POUSADA) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2.

Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30, 2007.

Product Applications:

Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly.

In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes.

Lanreotide also shows activity against non-endocrine tumors, e, along with other somatostatin analogues, is being studied as a possible general antitumor agent.

Lanreotide ,The main side effects of lanreotide treatment are mild to moderate pain at the injection site and gastrointestinal disturbances, such as diarrhea, nausea and vomiting. Isolated cases of gallstone formation have been associated with use of lanreotide, particularly over long periods of time.